Multiple sclerosis is a chronic demyelinating disease of the central nervous system. The underlying cause of this disease is not known, but Epstein-Barr virus is thought to be a possible culprit. However, most people infected with this common virus do not develop multiple sclerosis, and it is not feasible to directly demonstrate causation of this disease in humans. Using data from millions of US military recruits monitored over a 20-year period, Bjornevik et al. determined that Epstein-Barr virus infection greatly increased the risk of subsequent multiple sclerosis and that it preceded the development of disease, supporting its potential role in the pathogenesis of multiple sclerosis (see the Perspective by Robinson and Steinman). —YN

The authors highlight that they have confirmed that the antibody response in the treated patients was significantly lower than in the control groups, in some cases virtually absent, and that this is likely at least partially due to the impaired humoral responses seen in these groups. As well as this, the T cell response to the spike protein is significantly muted in fingolimod-treated patients. The correlation analyses helped show that the length of treatment and reduced capacity to respond to the antibody is likely linked.

The findings suggest that the interactions between the host and the microbiota are reciprocal, although more extensive work is required to confirm this. Moreover, evidence indicates that changes in microbiota composition may result in imbalances that could result in disease, with the gut as a potential novel therapeutic avenue. By understanding the biological effects of aberrant gut microbiome composition, it is possible to contemplate current therapeutic options and their efficacy. Ultimately, more research is necessary in this field, but targeting the gut microbiota may lead to the development of novel therapeutic strategies.

Multiple sclerosis is one of the most detrimental progressive diseases that doesn’t have a cure. Even if it were to be caught early, the current treatment can only slow the progression of multiple sclerosis by reducing nerve cell inflammation and damage. Basically, multiple sclerosis is where the protective coating of nerves in the spinal cord and the brain gets damaged and destroyed by the body’s own immune system. So it can lead to symptoms such as vision loss, muscle spasms, and impaired coordination. Unfortunately, the cause of this disease is unknown.

Progress in finding new treatments for neurologic disorders is often slow and incremental, and it rarely yields therapies that inhibit progression of these diseases. Treatment usually focuses on relieving symptoms. An exception to this pattern is treatment for multiple sclerosis (MS). In the late 1980s, researchers began trials on interferon beta-1b, a drug that was shown to modify MS activity. It was approved by the US Food and Drug Administration (FDA) in 1993.

Multiple sclerosis (MS) is an autoimmune disease. With these conditions, your immune system mistakenly attacks healthy cells. In people with MS, the immune system attacks cells in the myelin, the protective sheath that surrounds nerves in the brain and spinal cord. Dr. David Greene Arizona is developing stem cell therapies to treat these disorders and many autoimmune diseases.

New research shows that the Epstein-Barr virus, a common type of herpes virus, triggers multiple sclerosis by priming the immune system to attack the body’s own nervous system.

Physicians prescribe baclofen to treat muscle spasms and stiffness in patients with multiple sclerosis and spinal cord injuries. However, the established spinal canal delivery and tablet formulations have certain limitations. Tablets are unsuitable for people who have difficulty swallowing and injections, while getting more of the drug to target sites and addressing some side effects, can be painful.

Around 25% of patients with multiple sclerosis have blood antibodies that bind to the Epstein-Barr virus and EBNA1, a protein made in the brain and spinal cord. Researchers say this is the first study to definitely show that the Epstein-Barr virus can cause multiple sclerosis in some patients.

Study findings indicate that people with multiple sclerosis (MS) often experience challenges accessing appropriate healthcare services to address their disease-related needs, including symptom management. One option for improving access to care for patients with MS is to use mobile health (mHealth) technology, defined as the use of mobile and wireless devices to improve health outcomes, healthcare services, and health research.

Cette découverte soulève l'espoir du développement possible d'un futur traitement, qui permettrait de guérir cette maladie affectant environ 2,8 millions de personnes dans le monde.

Study findings indicate that people with multiple sclerosis (MS) often experience challenges accessing appropriate healthcare services to address their disease-related needs, including symptom management. One option for improving access to care for patients with MS is to use mobile health (mHealth) technology, defined as the use of mobile and wireless devices to improve health outcomes, healthcare services, and health research.

Êtes-vous un aidant pour une personne atteinte de sclérose en plaques? Téléchargez ce livret pour des conseils pratiques qui vous aideront à être un partenaire de soins en bonne santé.

Il suffit parfois d’un soutien pour avancer avec la maladie. Les aidants jouent un rôle essentiel auprès des patients atteints de sclérose en plaques. Ils apportent un soutien moral : ils réconfortent, rassurent, encouragent, apaisent. C’est fréquemment le premier confident du patient. L’aidant intervient aussi souvent dans la vie quotidienne : tâches ménagères, préparation des repas, courses et dossiers administratifs liés à la maladie.

These results indicate no association between hepatitis B vaccination and the development of multiple sclerosis.

Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.

In this video, we will be discussing the use of ice to help reduce spasticity and tightness!

Multiple sclerosis (MS) sufferers may develop a disabling condition severe enough to prevent them from continuing in employment or returning to work after a relapse. If as a MS sufferer you face permanent restrictions on being able to work you may be eligible for a social security disability benefit from the Social Security Administration (SSA).

The researchers found that compared with controls without autoimmune disease, 43 ICD-10 codes were recorded more frequently for patients with MS before diagnosis. In comparison to the other control groups, many of these findings were confirmed. A high proportion of these codes represent symptoms indicative of demyelinating events or other neurologic diseases.

Multiple sclerosis (MS) results in considerable financial burdens due to expensive treatment and high rates of disability, which could both impact care non-adherence. MS patients with lower financial self-efficacy and prior relapse history are at higher risk for financial toxicity, with associated care non-adherence and lower HRQOL.